Pocket Pivot - CAI - Biotechnology - September 17, 2026

Why this is a Pocket Pivot

CAI triggered a pocket pivot signal on September 17, 2026, one of six stocks the filter surfaced that day, ranking fourth. The stock closed up 9.61% on 1.78 times the prior session's volume, and that volume also exceeded the heaviest down day of the preceding ten sessions — the core signature of a pocket pivot: an accumulation day confirmed by an advance on heavy volume inside a healthy consolidation or uptrend, yet still short of a new high. The close stood above its 10-, 20-, 50-, 120- and 200-day moving averages, with the 20-day flattening and turning up while the 120-day kept rising, leaving the medium-term trend structure intact. On relative strength, RPS50 was 98.6 and RPS120 was 91.7, squarely in the leadership band the filter looks for.

How the filter reads it

Below are the dimensions the pocket pivot formula reads, and how CAI measured on September 17, 2026.

Dimension	Reading	Result
Volume	Advancing on heavy volume (+9.61%, volume 1.78x)	Pass
Trend structure	Moving averages stacked and rising	Pass
Price position	In the upper range	Pass
Relative Strength	In the leadership band (RPS50 98.6 / RPS120 91.7)	Pass
Signal uniqueness	First trigger in about a month	Yes

Fundamental Fact Sheet

Market Cap About USD 8.738 billion

PE (TTM) 3.23

Forward PE 82.33

ROE 20.13%

Net margin 10.62%

Revenue YoY +45.4%

Valuation metrics are from the latest snapshot; profitability and growth are trailing-twelve-month figures. These numbers are for reference only and do not constitute investment advice. Data sources and calculation methods may differ from official filings; verify independently before making any decision.

Caris Life Sciences is a Nasdaq-listed precision oncology molecular testing company that styles itself a next-generation AI TechBio business. Its core technology pairs whole-genome sequencing (WGS) with AI algorithms, and it has processed more than one million molecular profiles to date. The model is mainly B2B, paid for by hospitals, oncology practices and pharmaceutical companies. Within Q2 2026 revenue, molecular profiling services accounted for about 95.7% and pharma R&D services about 4.3%.

Growth

Q2 2026 revenue was USD 264 million, up 45.4% year on year. Growth was driven mainly by price: clinical test ASP rose 30% year on year, with blended ASP breaking USD 3,850 for a record high.
Test volume rose 18% year on year and 12% quarter on quarter to roughly 59,200 cases — slower than revenue, so the revenue elasticity comes mainly from higher value per test rather than from volume.
The earnings inflection is confirmed in the statements: full-year 2025 operating cash flow turned positive at USD 83 million, with USD 33 million and USD 28 million in Q1 and Q2 2026 respectively, consistent with the direction of the profit improvement.

Business catalysts

The commercial ramp and reimbursement progress of Caris Detect, the multi-cancer early-detection blood test (MolDX / CMS submissions), during 2026: the product launched in July 2026 at USD 3,500, contributed no revenue in Q2, and starts contributing from Q3.
An additional USD 15-20 million of capex in Q3 2026 lifts capacity from what supports USD 1 billion of revenue to roughly three times that level.
Full-year revenue guidance was raised to USD 1.03-1.04 billion, up 27%-28% year on year, with Q4 growth expected to accelerate to 25%.

Risks

Valuation does not match the growth: the 3.23 trailing PE is distorted by one-off items inflating EPS, and the real anchor is a forward PE of 82.33 — the market is paying for two more years of high growth; PB is 14.77 against net assets of just USD 592 million.
The analysts' mean target of 27.54 sits below the latest price of 30.92, so sell-side consensus has not kept up with the tape; a -7.5% move over 250 days against +75.7% over 60 days is a divergence across time horizons.
Caris Detect showed early clinical sensitivity of 60.3% (roughly a 40% miss rate for stage I/II cancers), and the reimbursement timeline for early detection is unspecified, leaving the revenue slope unpredictable.

Back to the watchlist